Please login to the form below

Not currently logged in
Email:
Password:

Stemcentrx

This page shows the latest Stemcentrx news and features for those working in and with pharma, biotech and healthcare.

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Bluebird and Celgene BCMA CAR-T kicks off ASCO

ADCs on show include Pfizer and AbbVie’s cofetuzumab pelidotin, a PTK7-targeting drug that was picked up by the latter via its 2-16 purchase of Stemcentrx, though that deal

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Stemcentrx represents a good fit with AbbVie's oncology portfolio and is forecast to generate multibillion $revenue. ... Not content with the Stemcentrx acquisition, in April AbbVie also closed two other oncology deals:.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics